HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 9, 7165-7169, March 1, 2002

This Article Abstract Full Text (PDF) An addition or correction has been published All Versions of this Article: 277/9/7165    most recent C100714200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cain, S. A. Articles by Monk, P. N. Search for Related Content PubMed PubMed Citation Articles by Cain, S. A. Articles by Monk, P. N. Social Bookmarking                      What's this?

The Orphan Receptor C5L2 Has High Affinity Binding Sites for Complement Fragments C5a and C5a des-Arg^74*

Stuart A. Cain and Peter N. Monk

From the Department of Neurology, University of Sheffield Medical School, Sheffield, S10 2RX, United Kingdom

Received for publication, December 7, 2001, and in revised form, December 21, 2001

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The substantial variations in the responses of cells to the anaphylatoxin C5a and its desarginated form, C5adR⁷⁴, suggest that more than one type of cell surface receptor for these ligands might exist. However, only a single receptor for C5a and C5adR⁷⁴, CD88, has been characterized to date. Here we report that the orphan receptor C5L2/gpr77, which shares 35% amino acid identity with CD88, binds C5a with high affinity but has a 10-fold higher affinity for C5adR⁷⁴ than CD88. C5L2 also has a moderate affinity for anaphylatoxin C3a, but cross-competition studies suggest that C3a binds to a distinct site from C5a. C4a was able to displace C3a, suggesting that C5L2, like the C3a receptor, may have a low binding affinity for this anaphylatoxin. Unlike CD88 and C3a receptor, C5L2 transfected into RBL-2H3 cells does not support degranulation or increases in intracellular [Ca²⁺] and is not rapidly internalized in response to ligand binding. However, ligation of C5L2 by anaphylatoxin did potentiate the degranulation response to cross-linkage of the high affinity IgE receptor by a pertussis toxin-sensitive mechanism. These results suggest that C5L2 is an anaphylatoxin-binding protein with unique ligand binding and signaling properties.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Complement fragment C5a is a potent chemoattractant and anaphylatoxin that acts on all classes of leukocytes and on many other cell types including endothelial, smooth muscle, kidney, liver, and neuronal cells (1, 2). In addition to its proinflammatory effects, C5a has recently been shown to protect cells against toxic insult and to stimulate proliferation in neurons and hepatocytes (3-6), suggesting a wider role for C5a in homeostasis. C5a is rapidly desarginated by serum carboxypeptidase N to the less potent derivative C5adR⁷⁴,¹ the first stage in deactivation of anaphylatoxin activity (7). The dR⁷⁴ form has a different spectrum of bioactivity to intact C5a; for instance, in human basophils, stimulation by intact C5a causes the release of lipid mediators (e.g. leukotriene C4) and cytokines (e.g. interleukin-4 and interleukin-13), whereas C5adR⁷⁴ stimulates only cytokine release (8). Antagonists can also discriminate between different cell types: a cyclic peptide is 30-fold more potent on human neutrophils than a linear peptide antagonist, but both peptides are equally potent on human umbilical artery macrophages (9). Wide variations in antagonist affinity have also been observed in different species, but the sequences of C5a receptor homologs in these species do not suggest an obvious mechanism for these variations (10). The molecular basis for the ability of different cell types to discriminate between agonists, antagonists, and intact C5a/C5adR⁷⁴ has yet to be elucidated as only a single receptor for C5a (CD88), a member of the G protein-coupled receptor superfamily, has so far been cloned (11, 12). CD88 is in a G protein-coupled receptor subfamily that contains the receptors for human C3a (C3aR), formyl peptide, and an orphan receptor, C5L2 (also known as gpr77) (13, 14). C5L2 transcripts are widespread with expression demonstrated in spleen, testis, brain, heart, lung, liver, kidney, ovary, and colon and in granulocytes and dendritic cells but not monocyte-derived macrophages (13, 14). Here we report that C5L2 has high affinity binding sites for both C5a and C5adR⁷⁴, apparently with a distinct binding site for the related anaphylatoxin C3a. Unlike CD88, C5L2 couples poorly to G_i-like G protein-mediated signaling pathways and does not undergo rapid receptor internalization in response to ligand binding.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Cell Lines and Culture Conditions-- RBL-2H3 cells were routinely cultured in Dulbecco's modified Eagle's medium + 10% (v/v) fetal calf serum, which was supplemented with 400 mg/liter G-418 for transfected cells, at 37 °C in 5% CO₂.

Cloning of C5L2 and C4a and Transfection of RBL Cells-- The C5L2 cDNA was cloned from a human brain (whole) Marathon-Ready cDNA (CLONTECH) by PCR using the sense primer 5'-GCGCGCAAGCTTGCCACCATGTACCCATACGACGTCCCAGACTACGCTGGGAACGATTCTGTCAGCTAC-3' and the antisense primer 5'-GGGCCCGAATTCCTACACCTCCATCTCCGAGAC-3'. The added HindIII and EcoRI restriction sites are shown respectively in italics, the Kozak sequence used is shown underlined, and the added human influenza hemagglutinin (HA) tag on the sense primer is shown in bold. After authentication by sequencing, the full-length PCR product was digested with EcoRI and HindIII (Roche Molecular Biochemicals) and ligated into the expression vector pEE6hCMV.neo (Celltech). The C3aR cDNA, a generous gift of P. Gasque (Cardiff, United Kingdom), was inserted into PEE6hCMV.neo vector at the same site. Stable transfection of RBL-2H3 cells was achieved by electroporation as previously described (15). An anti-HA tag monoclonal antibody (clone 12CA5, Roche Molecular Biochemicals) or C3aR (clone P4B4, a generous gift from P. Gasque) was used to sort the highest 5% of transfected cells on a Becton-Dickinson Vantage flow cytometer in three rounds of cell sorting. C4a was cloned from the same human brain library as C5L2 using the sense primer 5'-CCGCCGGGATCCAACGTGAACTTCCAAAAGGCGA-3' and the antisense primer 5'-GCACCTGGTACCCTATTATCGTTGGAGGCCCGCCT-3'; the added BamHI and KpnI restriction sites are shown respectively in italics.

Production of Anaphylatoxins-- Expression and purification of the recombinant His₆-tagged C5a, C5adR⁷⁴, C3a, and C4a was performed under denaturing conditions as described previously (9). C4a was also expressed and purified under nondenaturing conditions by sonication in the presence of BugBuster Protein Extraction Reagent (Novagen) using the conditions recommended by the manufacturer.

Cellular Activation Assays-- Cellular activation was measured as the release of -hexosaminidase from intracellular granules (16). The percentage of -hexosaminidase release was calculated as a percentage of the maximal release (1 µM C5a or C3a for CD88 and C3aR, respectively) or total cellular -hexosaminidase (C5L2). EC₅₀ and standard error values were obtained by iterative curve fitting using GraphPad Prism 2.0. Alternatively activation was assayed as the increase in intracellular [Ca²⁺] measured by flow cytometry of RBL cells labeled with the fluorescent indicator Fluo3AM (15).

Receptor Binding Assays-- Competition binding assays were performed using 50 pM ¹²⁵I-C5a or ¹²⁵I-C3a (PerkinElmer Life Sciences) on adherent C5aR-transfected RBL cells in 96-well microtiter plates at 4 °C as described previously (17). Binding curves were generated by incubating adherent cells in microtiter plates (at 55,000/well) with increasing concentrations of radiolabeled C5a and C3a in the presence or absence of 1 µM unlabeled anaphylatoxin. The IC₅₀, standard error values, and linear regression analyses were obtained by using GraphPad Prism 2.0.

Receptor Internalization Assays-- These were performed as described previously (18). Transfected RBL cells were incubated with 100 nM ligand to stimulate receptor internalization, which was determined as the loss of surface receptor using specific monoclonal antibodies for CD88 (clone S5/1, Serotec), C3aR (clone P4B4), and HA tag at 10 µg/ml.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

C5L2 and CD88 Have Very Similar Binding and Activation-related Sequences-- A sequence alignment between CD88, C3aR, and C5L2 is shown in Fig. 1. The N termini of CD88 and C5L2 contain several acidic residues that are characteristic of complement fragment receptors and that, for CD88 at least, form a part of the ligand binding site (19). Both CD88 and C3aR have been shown to have distinct ligand binding and activation sites (20). Receptor activation by ligand involves the engagement of charged and uncharged residues on the extracellular faces of the transmembrane helices. For CD88, these include Ile¹¹⁶, Val²⁸⁶, Arg¹⁷⁵, Glu¹⁹⁹, Arg²⁰⁶, and Asp²⁸² (21-23); C3aR has conserved residues at most analogous positions (Fig. 1). Interestingly C5L2 shares all of these residues except for Asp²⁸², where there is a Glu residue (boxed residues in Fig. 1). Thus C5L2 has a similar acidic ligand-binding N-terminal domain to CD88 and a similar ligand activation domain.

View larger version (37K): [in this window] [in a new window]   Fig. 1.   Sequence alignment of C5L2 (gpr77) with CD88 and C3aR. Transmembrane domains are underlined. Residues involved in receptor activation by ligand in CD88 (Swiss-Prot accession no. P21730) and conserved in C5L2 (gpr77) (accession no. Q9P296) and the C3aR (accession no. Q16581) are shown boxed by solid lines; the "DRY" motif residues are marked by *, and the intracellular loop 3 Ser/Thr-containing motif is marked by +.

C5L2 Binds Multiple Complement Fragments-- C5L2 was cloned from a human brain cDNA library and expressed as a stable transfectant in the rat basophilic leukemia line RBL-2H3. Antibodies against an N-terminal HA peptide, inserted after the initiating methionine of C5L2, was used to select the top 5% of expressing cells by fluorescence-activated cell sorting in three rounds of cell sorting. Anti-HA antibody, but not anti-CD88 or anti-C3aR monoclonal antibody, recognized these cells (data not shown). Binding assays were performed using ¹²⁵I-C5a and ¹²⁵I-C3a to determine the ligand specificity. The specific binding curve indicates that specific, saturable binding of C5a occurs (Fig. 2a) with a receptor number calculated from the B_max value of 39,736 ± 5,993/cell, mean ± S.E., n = 3. C3a also binds specifically (Fig. 2b) with a similar number of binding sites (25,652 ± 10,237/cell, mean ± S.E., n = 3; not significantly different from the C5a binding site number), but the calculated affinity for C5a was higher than that for C3a. Ligand specificity was investigated further using competition binding analysis, preincubating cells with a number of potential ligands prior to the addition of ¹²⁵I-C5a or ¹²⁵I-C3a (Table I). Using ¹²⁵I-C5a, the IC₅₀ for C5a was similar to that observed with CD88 in RBL cells, but C5L2 had a 10-fold lower IC₅₀ for C5adR⁷⁴ than CD88 (Table I). In contrast, C3a and C4a were very poor competitors for ¹²⁵I-C5a binding to both C5L2 and CD88 (Table I). A very different pattern was observed using ¹²⁵I-C3a: C5a, C4a, and C3a all had similar IC₅₀ values for ¹²⁵I-C3a binding to C5L2 (Table I), whereas C5adR⁷⁴, a very effective competitor for ¹²⁵I-C5a binding, had no detectable ability to compete for ¹²⁵I-C3a binding (Table I). This pattern is clearly different to that observed for C3aR (Table I) where both C3a and C4a competed much more effectively with ¹²⁵I-C3a than C5a or C5adR⁷⁴. These data demonstrate that C5L2 has a high affinity binding site for C5a and C5adR⁷⁴ and that C3a (and possibly also C4a) is a low affinity ligand for C5L2. It is likely that the binding sites for C5a and C3a on C5L2 are distinct because of the complex pattern of competition between ligands, in particular the complete failure of C5adR⁷⁴ to compete with ¹²⁵I-C3a. The location of the C3a binding site is, however, unclear as C5L2 does not have the very large second extracellular loop that appears to form the binding site for C3a on C3aR (24). The binding of C4a to C3aR has been previously observed (25), albeit with a larger difference between C3a and C4a affinities than observed here. The relatively high binding activity of the recombinant C4a used here may be due to the production process, which did not include the denaturation/refolding step used for C5a and C3a. Denaturation of C4a in urea during purification appeared to destroy both the C5L2 and C3aR binding activity.

View larger version (16K): [in this window] [in a new window]   Fig. 2.   Specific binding of C5a and C3a to RBL cells expressing C5L2. C5L2-transfected RBL cells, which were adhered to microtiter plates (55,000/well), were incubated with increasing concentrations of either 125I-C5a (a) or 125I-C3a (b) at 4 °C and then extensively washed. Results are shown as dpm/well after subtraction of nonspecific binding in the presence of 1 µM unlabeled ligand. The insets show Bmax and Kd values obtained by linear regression analysis from three separate experiments performed in triplicate.

C5L2 Couples Weakly to Intracellular Signaling Pathways-- The ligand binding data suggested the possibility that the high affinity of C5L2 for C5adR⁷⁴ might explain the sensitivity of some cell types to this ligand. We examined this by assessing the ability of C5L2 to activate transfected RBL cells using the degranulation response to ligand binding. The C5L2 ligands (C5a, C4a, C3a, and C5adR⁷⁴) were not able to support degranulation at concentrations of up to 3 µM (Fig. 3a). In contrast, C5a and C5adR⁷⁴ (EC₅₀ = 8 and 21 nM, respectively) could activate CD88-transfected RBL cells (Fig. 3b), and C3a (EC₅₀ = 52 nM) but not C4a could activate C3aR-transfected RBL cells (Fig. 3c). C5L2 also did not increase degranulation even when RBL cells were primed with phorbol 12-myristate 13-acetate (100 nM), a treatment that enhances the response to suboptimal stimuli in RBL cells (26), for 10 min prior to the addition of ligand (data not shown) (17). The failure of C4a to activate C3aR has been previously reported (25). The signaling activity of C5L2 was also assessed as the increase in intracellular Ca²⁺ using Fluo3AM-labeled RBL cells, an assay previously shown to be 10-fold more sensitive to ligand concentration than degranulation (15). Cells expressing C5L2 did not respond to 100 nM C5a, C5adR⁷⁴, C3a, or C4a (Fig. 3d), whereas RBL cells expressing CD88 responded to C5a and C5adR⁷⁴ with robust increases in cellular fluorescence (Fig. 3e), and RBL cells expressing C3aR responded to C3a but not to C4a (Fig. 3f). Identical patterns of activity were observed using 1 µM ligand (data not shown). The absence of intracellular Ca²⁺ signaling is not due to low receptor number because the receptor expression level for C5L2 (~40,000/cell) is actually higher than CD88 expression (~36,000/cell (17)). We then examined whether ligand binding to C5L2 could prime RBL cells for a subsequent stimulus through the tyrosine kinase-coupled high affinity IgE receptor, FcRI. C5L2-transfected RBL cells were incubated with IgE^DNP and activated by addition of 100 ng/ml HSA-DNP. Pretreatment for 10 min with 100 nM C5a, C3a, C4a, and C5adR⁷⁴ caused small but significant increases in the secretory response to HSA-DNP (Fig. 4). Untransfected cells did not show any increased response to HSA-DNP (Fig. 4), and the pretreatment of C5L2-transfected cells with pertussis toxin at a dose that could completely inhibit the degranulatory response to ligation of CD88 (10 ng/ml for 4 h (30)) also inhibited the effects of C5L2 ligands on the HSA-DNP response (Fig. 4). It appears that a low level of pertussis toxin-sensitive G protein-dependent signal transduction can occur following ligand binding to C5L2. The relatively weak coupling of C5L2 to G protein (probably G_i) is not surprising because C5L2 does not have a sequence corresponding to the DRY motif found in most chemoattractant and chemokine receptors (Fig. 1); CD88 has ¹³²DRF, C3aR has DRC, but C5L2 has DLC (Fig. 1). The arginine residue of this motif in particular has been shown to be important in coupling to G proteins; mutation of the analogous residue in formyl peptide receptor inhibits signaling because of uncoupling from G protein (27). In addition, the third intracellular loop of C5L2 is much shorter than that of CD88 and C3aR (Fig. 1) and lacks Ser/Thr residues that may be protein kinase C phosphorylation sites as well as a conserved basic region (²³⁹KTLK in CD88). Mutation of these Ser/Thr residues to Ala in CD88 inhibits signaling but not ligand binding (18), suggesting that this loop plays an essential role in G protein coupling. RBL cells are regarded as an excellent model system for the expression of granulocyte chemoattractant receptors (28) with similar G proteins and other receptor-associated molecules. Platelet-activating factor receptor transfected into RBL cells (29) couples primarily to pertussis toxin-insensitive G proteins, demonstrating that different types of G proteins are available for stimulus-secretion coupling in the RBL cell line. We conclude therefore that C5L2, despite being expressed at high levels on granulocytes (13), couples only poorly to the normal range of G proteins for a granulocyte chemoattractant receptor. The possibility that C5L2 has additional signaling functions that do not require G_i protein activation cannot be excluded. This might occur, for example, by the receptor phosphorylation-dependent mechanism utilized by C3aR for chemokine production (30).

View larger version (23K): [in this window] [in a new window]   Fig. 3.   Degranulation and intracellular [Ca2+] responses of transfected RBL cells. RBL cells transfected with C5L2 (a and d), CD88 (b and e), or the C3a receptor (c and f) were tested for secretion of -hexosaminidase (a-c; means of three separate experiments) or changes in fluorescence of the intracellular Ca2+ indicator Fluo3 (d-f; one experiment performed in duplicate) during incubation with 100 nM C5a (), C5adR74 (), C4a (), or C3a () or 1 µM calcium ionophore A23187 (, broken line). MC, median channel number.

View larger version (21K): [in this window] [in a new window]   Fig. 4.   Potentiation by C5L2 ligands of the degranulation response to cross-linkage of the high affinity IgE receptor. RBL cells transfected with C5L2 or untransfected control cells were incubated overnight with 1 µg/ml IgEDNP and then treated with buffer or 100 nM C5a, C5adR74, C4a, or C3a for 15 min prior to the addition of the cross-linking agent HSA-DNP at 100 ng/ml. Degranulation was assessed as the secretion of -hexosaminidase. In some cases cells were pretreated with 10 ng/ml pertussis toxin (PT) for 4 h prior to the addition of C5L2 ligands. Results are shown as a percentage of the release stimulated by 100 ng/ml HSA-DNP in the absence of anaphylatoxin (control = 100) and are means of three to six separate experiments performed in triplicate ± S.E. Significantly different from untransfected RBL cell response: ns, p > 5%; *, p < 5%; **, p < 0.5% (t test).

C5L2 Does Not Undergo Ligand-dependent Internalization-- CD88 and C3aR both undergo ligand-dependent internalization (25) when expressed in RBL cells, and so the ability of ligands (100 nM C5a, C5adR⁷⁴, C4a, and C3a) to stimulate C5L2 internalization was investigated using anti-HA antibody to measure surface expression. None of the C5L2 ligands induced internalization after a 10-min incubation at 37 °C, although 55% of surface CD88 and 75% of surface C3aR internalized after 10 min of treatment by 100 nM C5a/C5adR⁷⁴ or C3a, respectively (Fig. 5). The broad expression pattern and ligand preference of C5L2 initially suggested the possibility that C5L2 may act as a "sink" for excess anaphylatoxin following activation of the complement cascade, analogous to the Duffy and D6 promiscuous chemokine-binding proteins that may function in the buffering and presentation of chemokines (31). As it is not rapidly internalized, C5L2 is unlikely to be involved in anaphylatoxin clearance but might act as a reservoir of cell surface-associated anaphylatoxin to aid chemotaxis or to buffer anaphylatoxin concentrations during an inflammatory response. Alternatively, although internalization and receptor desensitization are not directly correlated, the retention of ligated C5L2 at the cell surface may be involved in prolonging signaling beyond the rapid responses normally stimulated by C5a.

View larger version (20K): [in this window] [in a new window]   Fig. 5.   Ligand-dependent internalization of chemoattractant receptors. Transfected RBL cells were incubated with the stated ligands at 37 °C for 10 min. After quenching in ice-cold buffer, surface expression of receptors was measured by adding antibodies specific for the N termini of CD88 and C3aR and the N-terminal HA tag of C5L2 and quantifying bound antibody levels by flow cytometry. The results are shown as a percentage of the untreated control cell expression and are the means ± S.E. of three separate experiments performed in duplicate. Significantly different from control (=100): *, p < 5%; ns, p > 5% (one sample t test). NA, no addition.

In conclusion, we have shown that C5L2 has high affinity binding sites for C5a and C5adR⁷⁴ and also binds C3a and C4a with a similar affinity to C3aR. However, C5L2 couples poorly to the intracellular signaling and internalization machinery used by other chemoattractant receptors. The functions of this novel anaphylatoxin-binding protein remain to be defined.

	FOOTNOTES

^* This research was funded by Arthritis Research Campaign Fellowship Grant M0543.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Neurology, E Floor, University of Sheffield Medical School, Beech Hill Rd., Sheffield, S10 2RX, United Kingdom. Tel.: 44-114-2261312; Fax: 44-114-2760095; E-mail: p.monk@shef.ac.uk.

Published, JBC Papers in Press, December 31, 2001, DOI 10.1074/jbc.C100714200

	ABBREVIATIONS

The abbreviations used are: dR⁷⁴, des-Arg⁷⁴; CD88, human C5a receptor; C3aR, human C3a receptor; RBL, rat basophilic leukemia; Fluo3AM, acetoxymethyl ester of Fluo3; HA, hemagglutinin; HSA-DNP, 2,4-dinitrophenol linked to human serum albumin; IgE^DNP, immunoglobulin E specific for 2,4-dinitrophenol.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				P. A. Ward Role of the complement in experimental sepsis J. Leukoc. Biol., March 1, 2008; 83(3): 467 - 470. [Abstract] [Full Text] [PDF]

				S. Paglialunga, P. Schrauwen, C. Roy, E. Moonen-Kornips, H. Lu, M. K C Hesselink, Y. Deshaies, D. Richard, and K. Cianflone Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice J. Endocrinol., August 1, 2007; 194(2): 293 - 304. [Abstract] [Full Text] [PDF]

				A.-M. Scola, A. Higginbottom, L. J. Partridge, R. C. Reid, T. Woodruff, S. M. Taylor, D. P. Fairlie, and P. N. Monk The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding J. Biol. Chem., February 9, 2007; 282(6): 3664 - 3671. [Abstract] [Full Text] [PDF]

				K. Johswich, M. Martin, J. Thalmann, C. Rheinheimer, P. N. Monk, and A. Klos Ligand Specificity of the Anaphylatoxin C5L2 Receptor and Its Regulation on Myeloid and Epithelial Cell Lines J. Biol. Chem., December 22, 2006; 281(51): 39088 - 39095. [Abstract] [Full Text] [PDF]

				T. M. Woodruff, J. W. Crane, L. M. Proctor, K. M. Buller, A. B. Shek, K. de Vos, S. Pollitt, H. M. Williams, I. A. Shiels, P. N. Monk, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration FASEB J, July 1, 2006; 20(9): 1407 - 1417. [Abstract] [Full Text] [PDF]

				M. Maslowska, H. Legakis, F. Assadi, and K. Cianflone Targeting the signaling pathway of acylation stimulating protein J. Lipid Res., March 1, 2006; 47(3): 643 - 652. [Abstract] [Full Text] [PDF]

				N. P. Gerard, B. Lu, P. Liu, S. Craig, Y. Fujiwara, S. Okinaga, and C. Gerard An Anti-inflammatory Function for the Complement Anaphylatoxin C5a-binding Protein, C5L2 J. Biol. Chem., December 2, 2005; 280(48): 39677 - 39680. [Abstract] [Full Text] [PDF]

				S. E. Wenderfer, B. Ke, T. J. Hollmann, R. A. Wetsel, H. Y. Lan, and M. C. Braun C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr Mice J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3572 - 3582. [Abstract] [Full Text] [PDF]

				M. Honczarenko, M. Z. Ratajczak, A. Nicholson-Weller, and L. E. Silberstein Complement C3a Enhances CXCL12 (SDF-1)-Mediated Chemotaxis of Bone Marrow Hematopoietic Cells Independently of C3a Receptor J. Immunol., September 15, 2005; 175(6): 3698 - 3706. [Abstract] [Full Text] [PDF]

				D. S. Allen-Gipson, A. A. Floreani, A. J. Heires, S. D. Sanderson, R. G. MacDonald, and T. A. Wyatt Cigarette Smoke Extract Increases C5a Receptor Expression in Human Bronchial Epithelial Cells J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 476 - 482. [Abstract] [Full Text] [PDF]

				M. Huber-Lang, J. V. Sarma, D. Rittirsch, H. Schreiber, M. Weiss, M. Flierl, E. Younkin, M. Schneider, H. Suger-Wiedeck, F. Gebhard, et al. Changes in the Novel Orphan, C5a Receptor (C5L2), during Experimental Sepsis and Sepsis in Humans J. Immunol., January 15, 2005; 174(2): 1104 - 1110. [Abstract] [Full Text] [PDF]

				J. Godau, T. Heller, H. Hawlisch, M. Trappe, E. Howells, J. Best, J. Zwirner, J. S. Verbeek, P. M. Hogarth, C. Gerard, et al. C5a Initiates the Inflammatory Cascade in Immune Complex Peritonitis J. Immunol., September 1, 2004; 173(5): 3437 - 3445. [Abstract] [Full Text] [PDF]

				H. Boshra, J. Li, R. Peters, J. Hansen, A. Matlapudi, and J. O. Sunyer Cloning, Expression, Cellular Distribution, and Role in Chemotaxis of a C5a Receptor in Rainbow Trout: The First Identification of a C5a Receptor in a Nonmammalian Species J. Immunol., April 1, 2004; 172(7): 4381 - 4390. [Abstract] [Full Text] [PDF]

				J. Ratajczak, R. Reca, M. Kucia, M. Majka, D. J. Allendorf, J. T. Baran, A. Janowska-Wieczorek, R. A. Wetsel, G. D. Ross, and M. Z. Ratajczak Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow Blood, March 15, 2004; 103(6): 2071 - 2078. [Abstract] [Full Text] [PDF]

				P. J. Havel Update on Adipocyte Hormones: Regulation of Energy Balance and Carbohydrate/Lipid Metabolism Diabetes, February 1, 2004; 53(90001): S143 - 151. [Abstract] [Full Text]

				M. Otto, H. Hawlisch, P. N. Monk, M. Muller, A. Klos, C. L. Karp, and J. Kohl C5a Mutants Are Potent Antagonists of the C5a Receptor (CD88) and of C5L2: POSITION 69 IS THE LOCUS THAT DETERMINES AGONISM OR ANTAGONISM J. Biol. Chem., January 2, 2004; 279(1): 142 - 151. [Abstract] [Full Text] [PDF]

				M. C. H. Holland and J. D. Lambris A Functional C5a Anaphylatoxin Receptor in a Teleost Species J. Immunol., January 1, 2004; 172(1): 349 - 355. [Abstract] [Full Text] [PDF]

				A. A. Floreani, T. A. Wyatt, J. Stoner, S. D. Sanderson, E. G. Thompson, D. Allen-Gipson, and A. J. Heires Smoke and C5a Induce Airway Epithelial Intercellular Adhesion Molecule-1 and Cell Adhesion Am. J. Respir. Cell Mol. Biol., October 1, 2003; 29(4): 472 - 482. [Abstract] [Full Text] [PDF]

				M. S. Huber-Lang, J. V. Sarma, S. R. McGuire, K. T. Lu, V. A. Padgaonkar, E. M. Younkin, R. F. Guo, C. H. Weber, E. R. Zuiderweg, F. S. Zetoune, et al. Structure-Function Relationships of Human C5a and C5aR J. Immunol., June 15, 2003; 170(12): 6115 - 6124. [Abstract] [Full Text] [PDF]

				T. MONSINJON, P. GASQUE, P. CHAN, A. ISCHENKO, J. J. BRADY, and M. FONTAINE Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells FASEB J, June 1, 2003; 17(9): 1003 - 1014. [Abstract] [Full Text] [PDF]

				Y. Kawasawa, L. M. McKenzie, D. P. Hill, H. Bono, RIKEN GER Group, GSL Members, and M. Yanagisawa G Protein-Coupled Receptor Genes in the FANTOM2 Database Genome Res., June 1, 2003; 13(6): 1466 - 1477. [Abstract] [Full Text] [PDF]

				D. Kalant, S. A. Cain, M. Maslowska, A. D Sniderman, K. Cianflone, and P. N. Monk The Chemoattractant Receptor-like Protein C5L2 Binds the C3a des-Arg77/Acylation-stimulating Protein J. Biol. Chem., March 21, 2003; 278(13): 11123 - 11129. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) An addition or correction has been published All Versions of this Article: 277/9/7165    most recent C100714200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend